FDA Says Actos May Raise Risk of Bladder Cancer
FDA Concludes Actos May be Linked to Bladder Cancer. The U.S. Food and Drug Administration (FDA) has concluded that pioglitazone, sold under the brand names Actos, Actoplus Met, Actoplus Met [...]